TIQRX Mutual Fund

TIQRX Mutual Fund

NAV$53.72
See how much of TIQRX you already own
Just $25 once·$69/mo·Download sample
X-ray my portfolio free

Fund Essentials - as of May 31, 2026

Net Assets
$637M
Expense Ratio
0.29%
Dividend Yield (Current)
1.92%
Holdings
2,584
Inception Date
Mar 31, 2006
Fund Family
Nuveen
Investment Style
PRO
Asset Class
PRO
Legal Structure
PRO
Dividend Frequency
Annually

Performance

YTD+9.83%
1 Year+19.26%
3 Year+18.39%
5 Year+11.30%
10 Year+14.12%

Asset Allocation

Stocks: 94.58%
Bonds: 5.42%
See how much of TIQRX you already own
Your funds unpacked, overlap, fees and score, free on screen. The full report is $25, once. Download sample.
X-ray my portfolio free

Top Holdings

View All →
TickerNameWeight
NVDANvidia Corp.6.80%
AAPLApple, Inc6.20%
MSFTMicrosoft Corp4.60%
AMZNAmazon.Com Inc3.60%
GOOGAlphabet Inc. C3.00%
Top 10 Concentration: 33.30%Report Date: May 31, 2026
Download all 2584 holdings for TIQRX
CSV export with sector, industry & share changes
Get CSV

Dividend Summary

View Details →
Dividend Yield (Current)
1.92%
Frequency
Annually
Latest Distribution
$0.63
-

Peer Comparison

Benchmark
PRO
Peer outperformance: PRO
Category rank: PRO
This Mutual Fund
PRO
Peer Avg
PRO

TIQRX Mutual Fund Overview

TIQRX Mutual Fund (Nuveen Equity Index Fund Retirement Class) is managed by Nuveen with $637.4M in net assets. TIQRX expense ratio is 0.29%, holding 2584 positions across sectors including Information Technology, Consumer Discretionary, Communication Services. Inception date: 2006-03-31.

TIQRX performance shows a YTD return of 9.83%. The 1-year return is 19.26% and the 5-year return is 11.30%. TIQRX dividend yield stands at 1.92%, paid annually.

TIQRX top holdings include Nvidia Corp. (6.8%), Apple, Inc (6.2%), Microsoft Corp (4.6%), Amazon.Com Inc (3.6%), Alphabet Inc. C (3.0%). Go to all TIQRX holdings, TIQRX sectors, or TIQRX dividends.

TIQRX can be compared against other funds. Use TIQRX overlap to find shared positions, or TIQRX vs another fund for a side-by-side view. TIQRX alternatives are available via the screener, along with tax-loss harvesting opportunities.